Biomarkers in head and neck cancer

Hyunseok Kang; Christine H. Chung; Arlene A. Forastiere

doi:10.1007/978-3-319-27601-4_7

Biomarkers in head and neck cancer

Hyunseok Kang, Christine H. Chung, Arlene A. Forastiere

School of Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Biomarker research provides the opportunity to risk stratify patients based on identified prognostic and predictive markers. The need for such biomarkers is evident to improve response and survival outcomes in head and neck cancer through more rational patient selection for intensive curative regimens as well as palliative treatments. Advances in our understanding of genomics, epigenetics, and immunology of head and neck cancer are accelerating the discovery of new biomarkers. With the increasing availability of molecularly targeted therapeutics, it is very important to identify and validate biomarkers in the appropriate clinical setting to translate the advances into improved clinical outcome. This chapter focuses on human papillomavirus (HPV) status as a validated prognostic biomarker and discusses emerging prognostic and/or predictive biomarkers with potential for testing through prospective clinical trials. The availability of validated diagnostic assays and required multi-institutional trials for selected patients presents logistical challenges in biomarker research for head and neck cancer.

Original language	English (US)
Title of host publication	Head and Neck Cancer: Multimodality Management, Second Edition
Publisher	Springer International Publishing
Pages	149-162
Number of pages	14
ISBN (Electronic)	9783319276014
ISBN (Print)	9783319275994
DOIs	https://doi.org/10.1007/978-3-319-27601-4_7
State	Published - Jan 1 2016

Keywords

Head and neck cancer
Molecular biomarkers
Predictive and prognostic markers
Therapeutic targets

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1007/978-3-319-27601-4_7

Fingerprint Dive into the research topics of 'Biomarkers in head and neck cancer'. Together they form a unique fingerprint.

Cite this

@inbook{7ad99a3e4399484aaf8307ade718fa51,

title = "Biomarkers in head and neck cancer",

abstract = "Biomarker research provides the opportunity to risk stratify patients based on identified prognostic and predictive markers. The need for such biomarkers is evident to improve response and survival outcomes in head and neck cancer through more rational patient selection for intensive curative regimens as well as palliative treatments. Advances in our understanding of genomics, epigenetics, and immunology of head and neck cancer are accelerating the discovery of new biomarkers. With the increasing availability of molecularly targeted therapeutics, it is very important to identify and validate biomarkers in the appropriate clinical setting to translate the advances into improved clinical outcome. This chapter focuses on human papillomavirus (HPV) status as a validated prognostic biomarker and discusses emerging prognostic and/or predictive biomarkers with potential for testing through prospective clinical trials. The availability of validated diagnostic assays and required multi-institutional trials for selected patients presents logistical challenges in biomarker research for head and neck cancer.",

keywords = "Head and neck cancer, Molecular biomarkers, Predictive and prognostic markers, Therapeutic targets",

author = "Hyunseok Kang and Chung, {Christine H.} and Forastiere, {Arlene A.}",

year = "2016",

month = jan,

day = "1",

doi = "10.1007/978-3-319-27601-4_7",

language = "English (US)",

isbn = "9783319275994",

pages = "149--162",

booktitle = "Head and Neck Cancer: Multimodality Management, Second Edition",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Biomarkers in head and neck cancer

AU - Kang, Hyunseok

AU - Chung, Christine H.

AU - Forastiere, Arlene A.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Biomarker research provides the opportunity to risk stratify patients based on identified prognostic and predictive markers. The need for such biomarkers is evident to improve response and survival outcomes in head and neck cancer through more rational patient selection for intensive curative regimens as well as palliative treatments. Advances in our understanding of genomics, epigenetics, and immunology of head and neck cancer are accelerating the discovery of new biomarkers. With the increasing availability of molecularly targeted therapeutics, it is very important to identify and validate biomarkers in the appropriate clinical setting to translate the advances into improved clinical outcome. This chapter focuses on human papillomavirus (HPV) status as a validated prognostic biomarker and discusses emerging prognostic and/or predictive biomarkers with potential for testing through prospective clinical trials. The availability of validated diagnostic assays and required multi-institutional trials for selected patients presents logistical challenges in biomarker research for head and neck cancer.

AB - Biomarker research provides the opportunity to risk stratify patients based on identified prognostic and predictive markers. The need for such biomarkers is evident to improve response and survival outcomes in head and neck cancer through more rational patient selection for intensive curative regimens as well as palliative treatments. Advances in our understanding of genomics, epigenetics, and immunology of head and neck cancer are accelerating the discovery of new biomarkers. With the increasing availability of molecularly targeted therapeutics, it is very important to identify and validate biomarkers in the appropriate clinical setting to translate the advances into improved clinical outcome. This chapter focuses on human papillomavirus (HPV) status as a validated prognostic biomarker and discusses emerging prognostic and/or predictive biomarkers with potential for testing through prospective clinical trials. The availability of validated diagnostic assays and required multi-institutional trials for selected patients presents logistical challenges in biomarker research for head and neck cancer.

KW - Head and neck cancer

KW - Molecular biomarkers

KW - Predictive and prognostic markers

KW - Therapeutic targets

UR - http://www.scopus.com/inward/record.url?scp=85017074307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017074307&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-27601-4_7

DO - 10.1007/978-3-319-27601-4_7

M3 - Chapter

AN - SCOPUS:85017074307

SN - 9783319275994

SP - 149

EP - 162

BT - Head and Neck Cancer: Multimodality Management, Second Edition

PB - Springer International Publishing

ER -